NCT01107756 - A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen | Biotech Hunter

Enrollment

403

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Neoplasms (no Otherwise Specified)

Interventions

DRUG

LENOGRASTIM (GRANOGYTE 34)

Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert

Trial Locations (25)

1200

Investigational Site Number 43, Mbombela

1709

Investigational Site Number 51, Johannesburg

2000

Investigational Site Number 12387, Johannesburg

2193

Investigational Site Number 54, Sandton

2572

Investigational Site Number 47, Klerksdorp

4001

Investigational Site Number 13, Durban

4091

Investigational Site Number 14, Durban

4126

Investigational Site Number 012, eManzimtoti

6045

Investigational Site Number 31, Port Elizabeth

6530

Investigational Site Number 24, George

7460

Investigational Site Number 21, Cape Town

7500

Investigational Site Number 27, Cape Town

7800

Investigational Site Number 26, Cape Town

7925

Investigational Site Number 22, Cape Town

9301

Investigational Site Number 11, Bloemfontein

Unknown

Investigational Site Number 53, Alberton

Investigational Site Number 55, Benoni

Investigational Site Number 32, East London

Investigational Site Number 451, Pretoria

Investigational Site Number 48, Rustenburg

Investigational Site Number 25, Somerset West

Investigational Site Number 56, Vereeniging

0699

Investigational Site Number 44, Polokwane

0084

Investigational Site Number 42, Pretoria

0102

Investigational Site Number 41, Pretoria